id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-N-2252-0008,FDA,FDA-2020-N-2252,Public Meeting Transcript,Other,Transcript(s),2022-03-25T04:00:00Z,2022,3,2022-03-25T04:00:00Z,,2022-03-25T18:54:21Z,,0,0,0900006484fe3f39
FDA-2020-N-2252-0007,FDA,FDA-2020-N-2252,Final Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act; Public Meeting; Request for Comments,Notice,Request for Comments,2022-02-24T05:00:00Z,2022,2,2022-02-24T05:00:00Z,2022-05-24T03:59:59Z,2022-05-24T01:01:00Z,2022-03926,0,0,0900006484f9f5b5
FDA-2020-N-2252-0002,FDA,FDA-2020-N-2252,BsUFA II interim assessment transcript,Other,Transcript(s),2021-02-01T05:00:00Z,2021,2,2021-02-01T05:00:00Z,,2021-02-01T18:48:17Z,,0,0,0900006484a1290b
FDA-2020-N-2252-0001,FDA,FDA-2020-N-2252,Interim Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act; Public Meeting; Request for Comments,Notice,Request for Comments,2020-12-28T05:00:00Z,2020,12,2020-12-28T05:00:00Z,2021-03-30T03:59:59Z,2021-03-30T01:00:27Z,2020-28602,0,0,09000064849cc7ab